gastroparesis and glp 1 drugs Incidence of with GLP-1 Medications: Clinical Evidence GLP-1 Gastroparesis Lawsuit: Stomach Paralysis

13 Two meta-analyses of other GLP-1 RA CVOTs found that GLP-1 RAs were associated with greater rates of DR progression, but both studies found that the effect was driven by the extent of hemoglobin A1c reduction, rather than the medications themselves

The primary endpoint was change in bodyweight from baseline at 24 weeks, with 48 weeks included as a secondary outcome

Knudsen, L.B., Lau, J

Banting lecture

For example, within the book of business for Employers Health, a leading group purchasing organization for pharmacy benefits, 60 percent of clients exclude obesity drugs, 25 percent cover them after prior authorization and the remainder allow access without any restrictions